Can You Get Weight-Loss Drugs on the NHS?

GLP-1 receptor agonists — semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro) — represent the most significant advance in obesity treatment in a generation. Clinical trials demonstrated average body weight reductions of 15–22%, durable over two years, with parallel reductions in cardiovascular events, sleep apnoea, and type 2 diabetes incidence. NICE approved semaglutide for obesity treatment in 2023 under Technology Appraisal TA875, and tirzepatide followed in 2024.^[1] The eligible population — adults with a BMI of 35 or above plus at least one weight-related condition — is estimated at 3.4 million in England. Around 420,000 GLP-1 prescriptions were dispensed through NHS channels in 2024, but the majority cover established diabetes patients; only an estimated 35,000 — roughly 1% of those NICE has deemed eligible — are receiving them specifically for obesity.^[2] Access through NHS specialist weight management services is severely constrained: only around 60 such services exist in England, and global supply shortages driven by US demand have periodically restricted new NHS prescribing of semaglutide.^[3]

The economic case for broader access is compelling: obesity-related conditions cost the NHS an estimated £6.5 billion annually, and independent modelling suggests NHS-wide roll-out at current drug costs would fall within NICE's cost-effectiveness threshold.^[4] Those who cannot access the drugs on the NHS pay £200–400 a month privately — an option unavailable to the low-income patients with the highest obesity burden. The gap between NICE approval and meaningful NHS access is, in practice, a rationing decision dressed as an infrastructure constraint, and its costs will compound as obesity-related ill-health continues to grow.